1C0.F Celyad Oncology SA

Healthcare Oil, Gas & Consumable Fuels Frankfurt Exchange
0.2690 EUR
Close of Oct 4, 2026
0.1285 0.4550
Market cap
EUR 3.21M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 1C0.F undervalued?

Graham number

The Graham number of Celyad Oncology SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Celyad Oncology SA fundamental analysis

No fundamental analysis for Celyad Oncology SA yet.

Celyad Oncology SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Celyad Oncology SA

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Full company profile